FDA Panel Recommends BPC-157, TB-500, MOTS-C

What the Panel Decided

On July 23, 2026, the first day of a two-day meeting, the FDA Pharmacy Compounding Advisory Committee voted to recommend every peptide on its agenda that day for the 503A bulks list. That is the list of bulk drug substances that licensed 503A pharmacies are cleared to compound from for individual patients. The four peptides were BPC-157, KPV, TB-500 (a thymosin beta-4 fragment), and MOTS-C.

The votes on BPC-157 and KPV were close, 8-6 in favor with one member abstaining. Reporting from the meeting described the panel voting in favor of TB-500 and MOTS-C as well. Because the agenda listed two chemical variants for some substances, several peptides drew more than one vote, but the direction was the same across the day: the committee recommended inclusion.

The Day 1 Votes, Peptide by Peptide

For a plain-language explainer of the categories behind this vote, how removal from Category 2 differs from being added to the 503A bulks list, and why neither equals FDA approval, see our dated FDA peptide review timeline. If you are trying to sort the headlines, our guide on whether the FDA is banning peptides in 2026 walks through the two loudest myths.

The Panel Overruled the FDA’s Scientists

The most notable part of the day was not that the panel said yes. It was that it said yes against the FDA’s own recommendation. Ahead of the meeting, FDA staff published briefing documents that reached the same conclusion for each of the seven peptides: do not add them to the 503A bulks list. The staff applied the four-factor framework the agency uses for these decisions, physical and chemical characterization, historical use in compounding, evidence of effectiveness, and safety, and concluded that none of the seven met the bar.

The advisory committee is a separate body of outside experts. It weighed the same evidence together with stakeholder and patient testimony and landed on the opposite recommendation for all four Day 1 peptides. That split, agency scientists on one side and the advisory panel on the other, is why this vote drew national coverage. It is also why the precise wording matters: a recommendation that runs against staff analysis is a strong signal of where the debate is heading, but it does not carry the force of a rule.

What the Vote Does Not Change

It is easy to read a "yes" vote as "peptides are legal now." That is not what happened. Three things did not change on July 23.

Legality did not change. These peptides were not banned the day before the vote, and they are not newly legal the day after. Since April 2026 they have sat in a regulatory gray zone: removed from the restricted Category 2 list, but not yet added to the 503A bulks list, and not FDA-approved. The vote is a step in the process that could eventually add them to that list. It is not the addition itself.

FDA approval did not happen. None of these peptides is an FDA-approved drug, and this meeting was never about approval. The 503A bulks list is a compounding pathway, not a marketing approval. A compounded medication is prepared by a licensed pharmacy for a specific patient under a prescription; an FDA-approved drug has completed formal clinical trials for a specific indication. Those are different things, and the vote touched only the first.

Day-to-day access did not change. Patients who work with a licensed provider already access these peptides through a valid prescription filled by a licensed 503A compounding pharmacy. That pathway does not depend on the bulks-list label, so it is exactly the same today as it was last week.

What Happens Next

The committee recommends; the FDA decides. The agency is not bound by the panel, though it has historically weighed advisory recommendations heavily. To actually add a peptide to the 503A bulks list, the FDA has to complete formal notice-and-comment rulemaking: publish a proposed rule, open a public comment period, review the comments, and issue a final rule. That sequence routinely takes more than a year. So even after a favorable vote, the realistic horizon for a practical change in compounding access runs into 2027.

Day 2 and the Deferred Five

Day 2 of the meeting, July 24, covers the three remaining peptides on the agenda: Emideltide (DSIP), Semax, and Epitalon. Those votes had not been taken as of the Day 1 recap, and we will update our coverage once they are. Separately, five of the twelve peptides removed from Category 2 in April 2026, LL-37, GHK-Cu (injectable), Dihexa, Melanotan II, and PEG-MGF, are slated for a later advisory panel scheduled before the end of February 2027.

What It Means for You

If you already use peptide therapy through a provider, nothing about your prescription, your pharmacy, or your access changed because of this vote. If you have been watching the headlines and waiting for peptides to become "legal," the honest read is that the process moved a real step forward on July 23, but it is still a process, with rulemaking ahead and no instant change.

The steadier takeaway is the one that has been true throughout: the safest way to use these peptides, whatever the FDA ultimately decides, is under a licensed provider who prescribes a protocol suited to you, filled by a licensed pharmacy that tests what it ships. That is the pathway PeRx uses. For the full regulatory backstory, our FDA peptide review timeline and our July 2026 FDA peptide panel guide lay out how the pieces fit together.

Frequently Asked Questions

Reviewed by Dr. Cory Mellon, MD · Last reviewed July 2026